Table of Contents Author Guidelines Submit a Manuscript
TheScientificWorldJOURNAL
Volume 9, Pages 891-908
http://dx.doi.org/10.1100/tsw.2009.100
Review Article

Alzheimer's Disease: Another Target for Heparin Therapy

1Department of Internal Medicine, Geriatric Unit, Ospedale Maggiore Policlinico IRCCS, University of Milan, Italy
2Department of Neuroscience, Mario Negri Institute for Pharmacological Research, Milan, Italy

Received 24 May 2009; Revised 11 August 2009; Accepted 12 August 2009

Academic Editor: Rudy Tanzi

Copyright © 2009 Luigi Bergamaschini et al.

Citations to this Article [24 citations]

The following is the list of published articles that have cited the current article.

  • Toshio Ariga, Tadashi Miyatake, and Robert K. Yu, “Role of proteoglycans and glycosaminoglycans in the pathogenesis of Alzheimer's disease and related disorders: Amyloidogenesis and therapeutic strategies - A review,” Journal of Neuroscience Research, vol. 88, no. 11, pp. 2303–2315, 2010. View at Publisher · View at Google Scholar
  • Adam M. Brustkern, Lucinda F. Buhse, Moheb Nasr, Ali Al-Hakim, and David A. Keire, “Characterization of Currently Marketed Heparin Products: Reversed-Phase Ion-Pairing Liquid Chromatography Mass Spectrometry of Heparin Digests,” Analytical Chemistry, vol. 82, no. 23, pp. 9865–9870, 2010. View at Publisher · View at Google Scholar
  • Nienke M. Timmer, Laura van Dijk, Catharina E.E.M. van der Zee, Amanda Kiliaan, Robert M.W de Waal, and Marcel M. Verbeek, “Enoxaparin treatment administered at both early and late stages of amyloid β deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain Aβ levels,” Neurobiology of Disease, vol. 40, no. 1, pp. 340–347, 2010. View at Publisher · View at Google Scholar
  • Dong-Hyuk Park, David J. Eve, Yong-Gu Chung, and Paul R. Sanberg, “Regenerative Medicine for Neurological Disorders,” Thescientificworldjournal, vol. 10, pp. 470–489, 2010. View at Publisher · View at Google Scholar
  • Dulce Papy-Garcia, Morin Christophe, Huynh Minh Bao, Siñeriz Fernando, Sissoeff Ludmilla, Sepúlveda Díaz Julia Elisa, and Raisman-Vozari Rita, “Glycosaminoglycans, protein aggregation and neurodegeneration,” Current Protein and Peptide Science, vol. 12, no. 3, pp. 258–268, 2011. View at Publisher · View at Google Scholar
  • Takahisa Kanekiyo, Juan Zhang, Qiang Liu, Chia-Chen Liu, Lijuan Zhang, and Guojun Bu, “Heparan Sulphate Proteoglycan and the Low-Density Lipoprotein Receptor-Related Protein 1 Constitute Major Pathways for Neuronal Amyloid-beta Uptake,” Journal Of Neuroscience, vol. 31, no. 5, pp. 1644–1651, 2011. View at Publisher · View at Google Scholar
  • Christina J. Malavaki, Achilleas D. Theocharis, Fotini N. Lamari, Ioannis Kanakis, Theodore Tsegenidis, George N. Tzanakakis, and Nikos K. Karamanos, “Heparan sulfate: biological significance, tools for biochemical analysis and structural characterization,” Biomedical Chromatography, vol. 25, no. 1-2, pp. 11–20, 2011. View at Publisher · View at Google Scholar
  • Robert Veerhuis, “Histological and direct evidence for the role of complement in the neuroinflammation of AD,” Current Alzheimer Research, vol. 8, no. 1, pp. 34–58, 2011. View at Publisher · View at Google Scholar
  • Burcu Baykal Minsky, Bingqian Zheng, and Paul L. Dubin, “Inhibition of Antithrombin and Bovine Serum Albumin Native State Aggregation by Heparin,” Langmuir, vol. 30, no. 1, pp. 278–287, 2014. View at Publisher · View at Google Scholar
  • Peipei Wang, and Kan Ding, “Proteoglycans and glycosaminoglycans in misfolded proteins formation in Alzheimer's disease,” Protein and Peptide Letters, vol. 21, no. 10, pp. 1048–1056, 2014. View at Publisher · View at Google Scholar
  • Deng-Feng Zhang, Jin Li, Huan Wu, Yue Cui, Rui Bi, He-Jiang Zhou, Hui-Zhen Wang, Chen Zhang, Dong Wang, Qing-Peng Kong, Tao Li, Yiru Fang, Tianzi Jiang, and Yong-Gang Yao, “CFH Variants Affect Structural and Functional Brain Changes and Genetic Risk of Alzheimer’s Disease,” Neuropsychopharmacology, 2015. View at Publisher · View at Google Scholar
  • Lian Li, Yan Li, Muhammad Ijaz, Muhammad Shahbaz, Qianqian Lian, and Fengshan Wang, “Review on complement analysis method and the roles of glycosaminoglycans in the complement system,” Carbohydrate Polymers, 2015. View at Publisher · View at Google Scholar
  • Clara Iannuzzi, Gaetano Irace, and Ivana Sirangelo, “The Effect of Glycosaminoglycans (GAGs) on Amyloid Aggregation and Toxicity,” Molecules, vol. 20, no. 2, pp. 2510–2528, 2015. View at Publisher · View at Google Scholar
  • Thomas J Paul, Harvey Kelly, Joshua Zuchniarz, Tahir Ahmed, and Rajeev Prabhakar, “Design of Heparin Oligosaccharide Based Molecules for Inhibition of Alzheimer Amyloid Beta (Aβ40) Aggregation,” Canadian Journal of Chemistry, 2016. View at Publisher · View at Google Scholar
  • Akihiro Onishi, Kalib St Ange, Jonathan S. Dordick, and Robert J. Linhardt, “Heparin and anticoagulation,” Frontiers In Bioscience-Landmark, vol. 21, pp. 1372–1392, 2016. View at Publisher · View at Google Scholar
  • Yishu Yan, Yang Ji, Nan Su, Xiang Mei, Yi Wang, Shanshan Du, Wenming Zhu, Chong Zhang, Yuan Lu, and Xin-Hui Xing, “Non-anticoagulant effects of low molecular weight heparins in inflammatory disorders: a review,” Carbohydrate Polymers, 2016. View at Publisher · View at Google Scholar
  • Xiang Zhou, and Lan Jin, “The Structure-Activity Relationship of Glycosaminoglycans and Their Analogues with beta-Amyloid Peptide,” Protein And Peptide Letters, vol. 23, no. 4, pp. 358–364, 2016. View at Publisher · View at Google Scholar
  • Katie L. Stewart, Eleri Hughes, Edwin A. Yates, David A. Middleton, and Sheena E. Radford, “Molecular Origins of the Compatibility Between Glycosaminoglycans and Aβ40 Amyloid Fibrils,” Journal of Molecular Biology, 2017. View at Publisher · View at Google Scholar
  • Katie L. Stewart, and Sheena E. Radford, “Amyloid plaques beyond A?: a survey of the diverse modulators of amyloid aggregation,” Biophysical Reviews, 2017. View at Publisher · View at Google Scholar
  • Jyun-Guo You, Yao-Wen Liu, Chi-Yu Lu, Wei-Lung Tseng, and Cheng-Ju Yu, “Colorimetric assay of heparin in plasma based on the inhibition of oxidase-like activity of citrate-capped platinum nanoparticles,” Biosensors and Bioelectronics, vol. 92, pp. 442–448, 2017. View at Publisher · View at Google Scholar
  • Carlos Ra?l Al?ez-Vers?n, Elena Lantero, and Xavier Fern?ndez-Busquets, “Heparin: new life for an old drug,” Nanomedicine, 2017. View at Publisher · View at Google Scholar
  • Julie Bejoy, Liqing Song, Zhe Wang, Qing-Xiang Sang, Yi Zhou, and Yan Li, “Neuroprotective Activities of Heparin, Heparinase III, and Hyaluronic Acid on the Aβ42-treated Forebrain Spheroids Derived from Human Stem Cells,” ACS Biomaterials Science & Engineering, 2018. View at Publisher · View at Google Scholar
  • Sergey P. Radko, Svetlana A. Khmeleva, Alexey B. Mantsyzov, Yana Y. Kiseleva, Vladimir A. Mitkevich, Sergey A. Kozin, and Alexander A. Makarov, “Heparin Modulates the Kinetics of Zinc-Induced Aggregation of Amyloid-β Peptides,” Journal of Alzheimer's Disease, pp. 1–12, 2018. View at Publisher · View at Google Scholar
  • Yuanwei Yan, Liqing Song, Julie Bejoy, Jing Zhao, Takahisa Kanekiyo, Guojun Bu, Yi Zhou, and Yan Li, “Modelling Neurodegenerative Microenvironment Using Cortical Organoids Derived from Human Stem Cells,” Tissue Engineering Part A, 2018. View at Publisher · View at Google Scholar